Skip to main content
. 2022 Jun 23;8:45. doi: 10.1186/s40942-022-00371-7

Table 1.

Distribution of vascular occlusion cases

n Diagnosis Gender Age Days until symptoms VA i VA f Severity of COVID Commorbility Hospitalization Treatment
1 CRVO M 52 22 20/400 20/20  +  No No Anti VEGF
2 M 65 90 20/1000 20/400  +  +  No No Anti VEGF
3 F 37 45 20/20 20/20  +  +  No No No
4 M 46 50 20/40 20/20  +  +  No No Anti VEGF
5 F 27 7 20/60 20/20  +  +  No No Anti VEGF
6 M 36 55 20/20 20/20  +  No No No
7 M 41 45 20/40 20/30  +  +  +  Dyslip No Anti VEGF
8 M 41 55 20/400 20/50  +  +  No No Anti VEGF
9 HMVO M 43 7 20/50 20/30  +  +  +  No Yes Anti VEGF
10 BRVO F 54 7 20/25 20/20  +  No No Ketorolac d
11 M 36 90 20/30 20/20  +  No No Anti VEGF
12 M 64 7 CF 20/200  +  +  No No Anti VEGF
13 CRAO M 73 7 LP LP  +  +  +  +  DM + HBP Yes No
14 M 47 7 LP LP  +  +  +  +  No Yes No

CRVO central retina vein occlusion, HMVO hemispheric vein occlusion, BRVO branch vein occlusion, CRVO central retina vein occlusion, Days until symptoms days after covid-19 infection until the onset of visual symptoms, VA i initial Visual acuity, VA f final Visual acuity, Dyslip: dyslipidemia, DM: Diabetes mellitus, HBP hight blood pressure, Ketorolac d drops

HHS Vulnerability Disclosure